Calling all🫀AHFTC and purveyors of #critcarecards
Now that #ACC26 is over, come spend a weekend in NYC at the #1 cardiac hospital to learn about what's new and exciting #CardiogenicShock #Transplant #LVAD #TAH and more! ONE month away.

✍️Register now: nyulmc.org/heartfailurecme

#HeartFailure

Topics include:
❄️ Static #lung preservation at 10° Celsius
🫁 #PGD-3 with #EVLP lung transplant versus standard LTX
⚙️ Escalating #MCS in patients with STEMI-related #cardiogenicshock
🌬️ Does open lung protective ventilation (OLPV) improve donor lung utilization?

#medsky #pulmsky #transplantsky

Join global leaders for the #ISHLTAcademy in Cardiogenic Shock: Real World Applications in Toronto. 🫀
📅 Tuesday, 21 April
➡️ Explore the program + register: 🔗 bit.ly/3ZSWH1W
🗣️ Academy Chairs: José González-Costello, Shelley Hall, Ezequiel Molina

#CardiogenicShock #ISHLT2026 #MedSky

Don’t let a "dry" patient fool you!
Euvolemic cardiogenic shock is a "dry & cold" trap. In acute hits like a massive MI, the cardiac index drops and SVR is sky-high, but there hasn't been time for fluid backup. Clear lungs don't rule out heart failure! #ICU #MedEd #CardiogenicShock

Making sense of the oxygen alphabet soup
ScvO2 (central) is our go-to via a standard line—it’s a reliable trend of oxygen delivery. SvO2 (mixed) is more "complete" but requires a Swan-Ganz. If ScvO2 drops, your pump is failing or consumption is too high. #ICU #MedEd #CardiogenicShock

Damage Control for the Failing Heart - Part 2 Cardiogenic shock in the ED: Spotting CS in heart failure. Staging severity. Phenotyping.

Damage Control for the Failing Heart - Part 2 (a blog series about cardiogenic shock in the ED).

Spotting cardiogenic shock in heart failure. Staging severity. Phenotyping.

#EmergencyMedicine #EM #EMedSky #EMSky #MedSky #cardiogenicshock

robertlloyd.substack.com/p/damage-con...

Grants for Lung and Heart Transplant Research Co-funded by the ISHLT and ISHLT Foundation ISHLT announced over $257,000 USD in funding for research designed to improve care for patients with advanced heart and lung disease. These funds were provided by the ISHLT Foundation.

Learn more about his work at 🔗 bit.ly/4qCGObN

#ISHLTResearchGrant #CardiogenicShock #TissuePerfusion #PatientCare

📜Read this month's #SCAIQIT on the Management of Non-Acute Myocardial Infarction #CardiogenicShock. Learn practical strategies for diagnosis, structured staging, and timely escalation of therapies to improve patient outcomes.

See the full tip➡️ https://ow.ly/gsLF50Y0PpA

#CardioSky

#ISHLT announced $257,000 USD in grants funded by the #ISHLTFoundation. These grants fund research in #CardiogenicShock, ex-vivo lung perfusion (#EVLP), and #AI #biomarkers in #LungTx. Congratulations to the grant recipients! 🎉🫀🫁

Learn more about their work at 🔗 https://bit.ly/4qCGObN

Cardiogenic Shock.

www.nejm.org/doi/full/10....

@nejm.org
#CardioSky #CardiogenicShock

#CardiogenicShock remains a high-mortality condition. Advances in precision medicine, diagnostics, and mechanical circulatory support offer promise; however, integrating these approaches into clinical practice requires careful consideration.

👉 buff.ly/AkFXyHa

Telehealth to Expedite Cardiogenic Shock Diagnosis and Treatment: A Case Report.
Boni, Rebecca L et al.
Paper
Details
#Telehealth #CardiogenicShock #CaseReport

⚡The MENA region’s leading cardiogenic shock meeting is back! Don’t miss the 3rd annual GHA -SCAI SHOCK Middle East meeting on January 9–10. Two days of #cardiogenicshock updates, hands-on learning, and multidisciplinary collaboration.

Register your team➡️ https://ow.ly/g83x50XHwNw

#CardioSky

SCAI: To improve cardiogenic shock outcomes, reduce lactate levels SCAI feels this is the best way forward to try lowering mortality rates, but the group is asking cardiologists to help by gathering more data. 

⚡SCAI's recently announced Door to Lactate Clearance initiative aims to improve #CardiogenicShock outcomes by measuring and reducing lactate levels. Learn more by watching this Cardiovascular Business interview with SCAI President Srihari Naidu, MD, MSCAI ➡️ https://ow.ly/lUMa50XuOCV

#CardioSky

🚨Happening tomorrow! Attend our webinar to gain expert guidance and actionable steps on treating #CardiogenicShock in women. This program will review the recent SCAI/EAPCI/ACVC consensus statement on this topic.

Register now➡️ https://scaipro.scai.org/URL/cs-in-women
#CardioSky
@escardio.bsky.social

Disparities in MCS Use for STEMI-Related Shock Seen Across the US The “uneven playing field” related to demographics could be smoothed by stroke networks and standardized care.

📣#STEMI patients who develop #CardiogenicShock are far less likely to receive #MCS if they’re female, Black, Asian/Pacific Islander or insured by #Medicaid. Steps must be taken to improve treatment and outcomes of these patients.

Learn more ➡️ https://ow.ly/QiVB50Xh7ZS

#CardioSky

JHLT: The Podcast: Cardiogenic Shock Working Group Nir Uriel, MD appears on JHLT: The Podcast to discuss the work of the Cardiogenic Shock Working Group and their recent paper on the outcomes of patients supported on Impella 5.5 .

On the #JHLT podcast last week, co-lead author Nir Uriel discussed the work of the Cardiogenic Shock Working Group and their recent paper on the outcomes of patients supported on Impella 5.5. Listen now!

#JHLTThePodcast #CardiogenicShock #CardioSky

www.ishlt.org/about/news-d...

📲 New in the SCAI Point-of-Care App:
• Alternative Access for #TAVR
• #CVD Guidelines
• #CardiogenicShock in Women Consensus
Access these clinical documents in the palm of your hand by downloading the app ➡️ scai.org/clinical-practice/qualit...

#CardioSky

🫀 New Webinar Alert! Join SCAI/EAPCI/ACVC on Nov 20 at 6 pm ET to review the recently released Expert Consensus Statement on #CardiogenicShock in Women. This collaborative session will analyze consensus key points and multiple case reviews.

Register today ➡️ https://ow.ly/s0QP50X8Jkz
#CardioSky

In last month's #ISHLTJournalWatch, #KatharinaFetten reviews a study on the association of agonal phase duration with heart utilization & post-transplant outcomes in #DCD #HeartTransplantation. 🫀

#ISHLT #CardiogenicShock #TransplantSky

In the second study for #ISHLTJournalWatch last month, #RamDuvuru reviews a 5-year study on the outcomes of #DCD #HeartTransplantation. 🫀

#ISHLT #CardiogenicShock #TransplantSky

Announcing the SCAI Door to Lactate Clearance Cardiogenic Shock Initiative: Definition, Hypothesis and Call to Action, a new initiative led by SCAI President Srihari S. Naidu, MD, MSCAI.

Read the full document ➡️ scai.org/publications...

#CardioSky #CardiogenicShock

👥 Attendees at #SCAISHOCK are exploring over 50 posters covering every aspect of #CardiogenicShock. The Welcome Reception is buzzing with engaging discussions, valuable insights, and excellent networking opportunities.

🔥 We are kicking off the 2025 #SCAISHOCK Precon Workshop here in Tampa! In this exclusive half-day program, attendees are diving into the essentials of building and strengthening a #CardiogenicShock program. Follow along as we post live updates from the conference ➡️ my.walls.io/SHOCK

#CardioSky

#pharmacology12
#CardiotonicAgents #Digoxin #Milrinone #Dobutamine #Dopamine #CardiacGlycoside #Beta1Agonist #Catecholamine #PhosphodiesteraseInhibitor #HeartFailure #CardiogenicShock #CardiacOutput #PositiveInotrope #NursingStudents #Pharmacology #MedSchool #CriticalCareNursing #NursingEducation

Age‐related differences in cardiogenic shock secondary to Takotsubo syndrome In this multicenter study of 408 patients with cardiogenic shock secondary to Takotsubo syndrome (CS-TTS), age emerged as a major determinant of clinical profile and prognosis, along with SCAI shock ....

🐙 Our latest paper about #CardiogenicShock in #Takotsubo is now out in European Journal of Clinical Investigation

Available here: doi.org/10.1111/eci....

#Cardiology #HeartFailure #OpenAccess

The second slide from the August 2025 issue of Journal Watch, titled "Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial." For a more screenreader friendly version, the full issue PDF is at https://www.ishlt.org/docs/default-source/journal-watch/2025-08-journalwatch-cardiology.pdf.

In the second study for #ISHLTJournalWatch last month, Max Berrill reviews a randomized #clinicaltrial from JACC about early #IABP for #HF-related #CardiogenicShock.

#CardioSky #TransplantSky

Cardiogenic Shock in Scotland – 3rd October 2025

Register and attend the one-day educational meeting with national experts in the fields of #Cardiology and #CritcalCare to discuss the management of #CardiogenicShock in Scotland 👉 www.scottishintensiv...

The first slide from the August 2025 issue of Journal Watch, titled "Safety and efficacy intravenous istaroxime up to 60 hours for patients with pre-cardiogenic shock." For a more screenreader friendly version, the full issue PDF is at https://www.ishlt.org/docs/default-source/journal-watch/2025-08-journalwatch-cardiology.pdf.

The first study this month is from @jhlt.bsky.social and explores the safety and efficacy of #istaroxime in patients with pre- #cardiogenicshock due to #AcuteHF. It's reviewed by Sumita Barua of St. Vincent's in Sydney.

We'll highlight the rest of the studies later this month.

4TEEN4 begins trial of antibody therapy for cardiogenic shock - PharmaTimes First patient dosed in phase 1b/2a study of procizumab

#4TEEN4 #4TEEN4Pharmaceuticals #antibodytherapy #cardiogenicshock #phase1b/2astudy #procizumab #monoclonalantibody #PROCARD1trial #circulatingdipeptidylpeptidase3 #cDPP3 #cardiacdepressionfactor #shock #cDPP3inhibitor #angiotensinII #PROCARD1study
pharmatimes.com/news/4teen4-...